Mammography Results and BI-RADS Agreement Among Women Participating in a Community Health Initiative in Uganda - Top-Institutions - MDSpire

Mammography Results and BI-RADS Agreement Among Women Participating in a Community Health Initiative in Uganda

  • By

  • Eric Kitongo

  • Enock Suubi Segawa

  • Nayiga Joyce

  • Nabbosa Valeria

  • Bugeza Samuel

  • Kibudde Solomon

  • November 28, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Oncology
    • Radiology
    • Cancer Epidemiology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Imaging
    • Surgical Oncology
    • Cancer Screening

  • #3

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Breast Imaging
    • Global Health
    • Cancer Prevention

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Cancer Epidemiology
    • Breast Cancer Screening
    • Radiology

  • #5

    University of Cape Town
    University of Cape Town

    Cape Town, Western Cape

    Key Differentiators

    • Breast Cancer Screening
    • Global Oncology
    • Radiology

Original Source(s)

Mammography Results and BI-RADS Agreement Among Women Participating in a Community Health Initiative in Uganda

  • by Eric Kitongo, Enock Suubi Segawa, Nayiga Joyce, Nabbosa Valeria, Bugeza Samuel, Kibudde Solomon

  • November 28, 2025

Related Content

Clinician Perspectives on Implementing Breast Cancer–Related Lymphedema Prospective Screening

Diagnostic value of multimodal ultrasound imaging in triple-negative breast cancer

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial